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RESUMO
Objetivos: Avaliar a prevalência de soropositividade 
para  toxoplasmose  em  gestantes,  investigar  os 
desfechos clínicos e a prevalência da toxoplasmose 
congênita e verificar a utilidade da triagem de rotina 
para Toxoplasma gondii em parturientes.
Métodos:  Estudo  prospectivo  incluindo  todas 
as  mães  e  seus  respectivos  recém-nascidos  vivos, 
durante os 12 primeiros meses de implantação, em 
uma  maternidade,  de  uma  rotina  de  triagem  para 
toxoplasmose em parturientes.
Resultados: Foi avaliado o estado imunológico 
para toxoplasmose em 2.477 (98,5%) entre as 2.513 mães 
de recém-nascidos vivos durante o período do estudo. 
Destas, 810 (32,7%; IC 95% 30,9-34,6%) eram suscetíveis 
e  1.667  (67.3%;  IC  95%  65,4-69,1%)  eram  imunes. 
Foram  diagnosticados  três  casos  de  toxoplasmose 
congênita apenas pela sorologia materna na hora do 
ABSTRACT
Aims: To determine the prevalence of seropositivity for 
toxoplasmosis in pregnant women, to assess the outcome and 
the prevalence of congenital toxoplasmosis, and to evaluate 
the usefulness of routine screening for Toxoplasma gondii 
antibodies in parturient women. 
Methods:  Prospective  cross-sectional  study  of 
consecutive mothers and their liveborn infants within the 
first 12 months of the implementation in a maternity ward 
of a routine consisting in screening for toxoplasmosis at 
delivery.
Results:  Serologic  status  for  toxoplasmosis  were 
assessed in 2,477 (98.5%) of  2,513 mothers of liveborn 
infants throughout the study period. Of the 2,477 mothers, 
810 (32.7%; 95%CI 30.9-34.6%) were susceptible and 1,667 
(67.3%; 95%CI 65.4-69.1%) were immune. Three newborn 
infants with congenital toxoplasmosis were identified because 
of the maternal serum tests at delivery, and all of them had 
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parto, sendo que os três pacientes apresentavam lesões 
ativas de retinocoroidite toxoplásmica A prevalência 
de toxoplasmose congênita foi de 12/10.000 (IC 95%: 
6/10.000-21/10.000).
Conclusões: A  sorologia  materna  no  momento 
do parto foi útil na identificação precoce de casos 
de  toxoplasmose  congênita  que  teriam  passado 
despercebidos  no  período  neonatal,  permitindo  o 
tratamento precoce de bebês com retinocoroidite. Nesta 
população, a elevada prevalência encontrada, tanto de 
anticorpos anti-Toxoplasma gondii nas gestantes, quanto 
de toxoplasmose congênita, justificam um programa 
de triagem pré-natal.
DESCRITORES:  TOXOPLASMOSE  CONGÊNITA/preven- 
ção  &  controle;  TOXOPLASMOSE  CONGÊNITA/diagnóstico; 
DIAGNóSTICO PRé-NATAL; ATENçãO PERINATAL; TRANS- 
MISSãO vERTICAL DA DOENçA; TRIAGEM.
active ocular lesions caused by toxoplasmic retinochoroiditis. 
The prevalence of congenital toxoplasmosis was 12/10,000 
(CI 95%: 6/10,000-21/10,000).
Conclusions: Maternal serologic screening at delivery 
was useful for the early detection of cases of congenital 
toxoplasmosis that would have otherwise gone undetected 
in the neonatal period, and allowed for earlier treatment 
of newborns with retinochoroiditis. The high prevalence 
of Toxoplasma gondii antibodies in pregnant women and 
of congenital toxoplasmosis justify a prenatal screening 
program in this population.
KEY WORDS: CONGENITAL TOXOPLASMOSIS/prevention 
& control; CONGENITAL TOXOPLASMOSIS/diagnosis; PrENATAL 
DIAGNOSIS;  PERINATAL  CARE;  DISEASE  TRANSMISSION, 
vERTICAL; SCREENING.
INTRODUCTION
Mother-to-child transmission of toxoplasmosis 
may occur when maternal infection by Toxoplasma 
gondii (T. gondii) is acquired during pregnancy. 
Even  though  the  involvement  of  the  central 
nervous system of the fetus is usually more severe 
in infections that occur during the first and second 
trimesters  of  gestation,  ocular  lesions  are  not 
influenced by gestational age and are frequent 
among fetuses infected during the last weeks of 
gestation – just when the rate of mother-to-child 
transmission is higher. In these cases, no abnormal 
findings are observed on physical examination, 
but the infants may show clinical abnormalities 
at complementary tests. On the other hand, the 
treatment for congenital toxoplasmosis is indicated 
even in subclinical infections, as the prognosis of 
this disease improves with early treatment and 
with its maintenance for at least 12 months.1-4
Since toxoplasmosis is asymptomatic in most 
pregnant  women  and  may  go  undetected  in 
newborn infants, its early diagnosis depends on 
a control strategy that is based on serologic testing 
during the prenatal and/or neonatal period. The 
choice of a strategy demands some information 
about the characteristics of the population, such 
as prevalence of immunity to T. gondii among 
women of childbearing age, and the burden of 
congenital  toxoplasmosis.5  In  populations  in 
which the prevalence of toxoplasmosis is high, 
it is recommendable to carry out prenatal tests, 
as in some European countries.6-8 In populations 
with a lower prevalence of the disease, alternative 
strategies (e.g.: neonatal screening) have been 
successful in the early detection of congenital 
toxoplasmosis among newborn infants.9-11
In the city of Porto Alegre, in southern Brazil, 
the prenatal care program implemented in 2001 
includes tests for T. gondii-specific IgG and IgM 
antibodies when starting prenatal care, which 
should be repeated in the seronegative pregnant 
women at the beginning of the third trimester. 
However,  this  program  did  not  take  into 
account the vulnerability of the third trimester 
of pregnancy, and it did not include any test at 
delivery. Researchers had already identified such a 
problem even in more rigorous prenatal screening 
programs. In these cases, fetal infections in the last 
weeks of gestation may go unnoticed in the first 
months of extrauterine life, until the infant shows 
signs of ocular or neurological involvement.12-14 
To get around this problem, routine serum tests 
for T. gondii in previously seronegative parturient 
women have been adopted in our hospital since 
May  2002.  In  addition,  serum  tests  are  also 
requested from mothers whose previous immune 
status are unknown, since many patients admitted 
to the obstetric ward of our hospital come from 
cities or towns where the investigation for T. 
gondii-specific antibodies is not a routine practice 
in prenatal care.
The major objective of this study was to assess 
whether the routine investigation of T. gondii-
specific antibodies in parturient women was able 
to detect cases of congenital toxoplasmosis which 
would not be otherwise identified at birth. The 
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to  toxoplasmosis  in  pregnant  women  and  of 
congenital toxoplasmosis in Porto Alegre, Brazil, 
identified some problems in the prenatal screening 
for toxoplasmosis, and described the evaluation of 
the infants at risk for congenital toxoplasmosis.
METHODS
A cross-sectional study was conducted at the 
public sector of the maternity ward of Hospital 
São Lucas, a teaching hospital from Pontifícia 
Universidade Católica do Rio Grande do Sul, 
from Porto Alegre, a city from southern Brazil. 
The study prospectively included all parturient 
women who gave birth to liveborn infants between 
May 1, 2002 and April 30, 2003 (first 12 months 
after the implementation of routine testing for T. 
gondii serology in parturient women).
The investigation of T. gondii-specific IgG and 
IgM antibodies was carried out in three situations: 
1) in patients without previous serum tests for 
toxoplasmosis, or with incomplete serum tests 
(only IgG or only IgM); 2) in those who were 
seronegative for toxoplasmosis during pregnancy; 
and 3) in those with evidence of recent infection 
(positive T. gondii-specific IgM). 
Testing  at  delivery  was  carried  out  at  the 
laboratory  of  Hospital  São  Lucas  using  the 
enzyme-linked fluorescent assay (ELFA) VIDAS
® 
(bioMérieux  S.A.,  Lyon,  France).  Serum  tests 
during pregnancy, when performed, were carried 
out at different laboratories, according to the sites 
of prenatal care, using different commercially 
available techniques. The T. gondii-specific IgG 
and IgM were considered positive or negative 
according to the reference values of the technique 
used. Test results, patient ages and data on the 
newborn  infants  were  prospectively  collected 
during the study period.
Newborn  infants  at  risk  for  congenital 
toxoplasmosis or with confirmed infection were 
investigated  and  treated  according  to  current 
recommendations,  and  the  follow-up  was 
carried out at the Outpatient Clinic of Congenital 
Infections  of  Hospital  São  Lucas.  The  cases 
of  congenital  toxoplasmosis  were  defined  by 
Lebech’s criteria.15
The data were analyzed by Epi Info 2002 and 
SPSS.  The  statistical  tests  included  frequency 
distribution and chi-square test for linear trends. 
The 95% confidence intervals were calculated by 
binomial distribution. 
The study protocol was in accordance with 
the ethical standards of the Helsinki Declaration 
of 1975, as revised in 1983, and was approved by 
the Ethics Committee of Pontifícia Universidade 
Católica do Rio Grande do Sul.
RESULTS
During the study period, 2,513 patients who 
gave birth to liveborn infants were admitted to the 
maternity ward. Serum tests for toxoplasmosis 
were not indicated for 1,190 parturient women, 
who presented positive T. gondii-specific IgG and 
negative T. gondii-specific IgM in the prenatal 
testing. Testing at delivery was carried out in 29 
patients who had positive T. gondii-specific IgM 
results during pregnancy (in four of them, the 
specific IgM was no longer positive at delivery); 
in 610 who were susceptible (of whom one patient 
presented positive IgG and IgM at delivery); and 
in 648 whose previous immune status was not 
known (Figure 1).
[*] Groups in which cases of congenital toxoplasmosis were detected
Figure 1 – Serologic status for T. gondii infection in 2,513 
consecutive
The previous immune status was unknown in 
these 684 parturient women due to the following 
reasons: lack of prenatal care in 199 (29%); no 
testing during prenatal care in 264 (39%); lack 
of documentation in 179 (26%); and incomplete 
serology in 42 (6%) – 23 only with IgG and 19 only 
with IgM antibody tests to T. gondii requested 
during prenatal care. Testing at delivery of these 
648 patients revealed that 447 (69%) were IgG-
  2,513  
parturient women 
1,190 igG(+) igM(-) in the pregnancy:  
testing not indicated 
1,323 
testing indicated 
29 igG/igM(+) 
in the pregnancy 
610  igG/igM(-) 
in the pregnancy 
648 tested 
36 not tested, 
remained 
unknown 
4 igG (+) igM(-) at 
delivery 
1 igG/igM(+) at delivery [*] 
201  igG/igM(-) 
432 igG(+) igM(-) 
15 igG/igM(+) [*] 
1,626 igG(+) igM(-)  41 igG/igM(+)  810  igG/igM(-) 
1,667 immune    810 susceptible 
 25 igG/igM(+) at 
delivery [*]  609  igG/igM(-) 
at delivery 
684 unknown in 
the pregnancy 
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positive (432 IgM-negative and 15 IgM-positive), 
and 201 (31%) were susceptible (IgG and IgM-
negative). 
Tests were inadvertently not requested for 
36 parturient women without prenatal testing, 
whose immune status for toxoplasmosis remained 
unknown. Therefore, of the 2,513 patients, we 
were  able  to  determine  the  serologic  status   
for  2,477  (98.6%),  of  whom  1,667  (67.3%;   
95%CI  65.4-69.1%)  had  positive  results  for  T. 
gondii-specific  IgG  (41  with  positive  IgM  at 
delivery) and 810 (32.7%; 95%CI 30.9-34.6%) were 
susceptible to toxoplasmosis (Figure 1).
Among the 41 patients with positive IgM at 
delivery, seven were identified as positive for 
antibodies to T. gondii in a previous pregnancy 
(residual  IgM).  Hence,  only  in  the  remaining   
34  cases,  there  was  a  likelihood  of  sero- 
conversion  during  pregnancy.  These  patients 
were investigated more closely:
–  In one case, fetal infection was detected in 
the second trimester of gestation, because 
of hydrocephalus on the fetal ultrasound. 
The patient was referred to the Division of 
Fetal Medicine, and fetal toxoplasmosis was 
diagnosed.
–  A woman who was seronegative during 
pregnancy  presented  seroconversion  in 
the last trimester of gestation, detected at 
delivery. The newborn infant had congenital 
toxoplasmosis.
–  Three patients with very high  T. gondii-
specific  IgG  and  IgM  concentrations  at 
the first test during pregnancy (two with 
negative fetal diagnosis and one without 
fetal  diagnosis)  had  been  treated  with 
spiramycin. Their newborn infants showed 
negative results for specific IgM antibodies 
and  no  evidence  of  congenital  infection. 
Two of these babies were followed up to 
the  complete  disappearance  of  maternal 
antibodies.
–  Two  patients  without  any  test  for  toxo- 
plasmosis  during  pregnancy  showed 
very  high  concentrations  of  T.  gondii-
specific  IgG  and  IgM  at  delivery,  and 
one  of  the  infants  was  diagnosed  with 
congenital toxoplasmosis. The other infant 
showed negative specific IgM and normal 
physical examination and complementary 
investigation, but was lost to follow-up.
–  In  one  pregnant  woman,  only  the  IgG 
antibodies  had  been  investigated  in  the 
second  trimester  of  gestation,  yielding 
positive result. At delivery, both specific 
IgG and IgM concentrations were extremely 
high. The newborn infant was diagnosed 
with congenital toxoplasmosis.
–  In the remaining 26 patients with positive T. 
gondii-specific IgM at delivery, the timing of 
infection could not be accurately determined. 
The serologic profile suggested residual IgM 
levels and indicated that toxoplasmosis had 
probably been acquired before pregnancy. 
All newborn infants were IgM-negative and 
none of them showed clinical evidence of 
congenital infection. Fourteen infants were 
followed up to the complete disappearance 
of T. gondii-specific IgG antibodies.
Therefore,  four  newborn  infants  were 
diagnosed  with  congenital  toxoplasmosis.  In 
one case, fetal infection was suspected because 
of hydrocephalus on the fetal ultrasound. Three 
cases  of  congenital  toxoplasmosis,  however, 
were identified only through routine maternal 
serology  at  delivery.  These  three  infants  had 
normal physical examination at birth, but further 
investigation revealed positive serology for T. 
gondii and cerebral calcifications in all of them, 
retinochoroiditis in two, and cerebral ventricular 
dilatation in one infant (Table 1). In all cases the 
specific treatment was started in the first days of 
life. One of them (patient 3) was identified later 
by neonatal screening, since a trial on neonatal 
screening for T. gondii-specific IgM antibodies was 
simultaneously being conducted in Porto Alegre 
with 10,000 newborn infants treated by the public 
health system, published elsewhere.16 The other 
three cases were not detected by that neonatal 
screening trial because they were born outside that 
study period, and screening for toxoplasmosis is 
not included in the public routine for neonatal 
screening in Porto Alegre.
By excluding the first patient in order to avoid 
selection bias (as the mother had been referred to 
the Division of Fetal Medicine), the prevalence of 
congenital toxoplasmosis in this study population 
was  3/2,476  liveborn  deliveries,  or  12/10,000 
(95%CI:  6/10,000-21/10,000).  Prevalence  of 
congenital  toxoplasmosis  in  live  newborns  of 
susceptible  mothers  was  35/10,000  (IC  95%: 
24/10,000-48/10,000).
Maternal  ages  ranged  between  12  and  45 
years  (median:  22  years).  There  was  a  linear 
trend towards an increase in the prevalence of 
antibodies to T. gondii with age (p=0.015). The 
increase was more pronounced after the age of 
30 years (Figure 2).Scientia Medica, Porto Alegre, v. 19, n. 1, p. 27-34, jan./mar. 2009  31
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Figure 2 – Rise in the prevalence of 
seropositivity for T. gondii according  
age of parturient women.
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TABLE 1 – Outcome of the infants with congenital toxoplasmosis.*
*  All infants were treated with pyrimethamine, sulfadiazine and folinic acid for 1 year and were given corticosteroids when active ocular lesions were present   
  (4 to 8 weeks).
** Serum tests of mothers at delivery, and of newborns, carried out by ELFA vIDAS® (IgG positive >8 IU/mL; IgM positive >0.65).
†  Patients 2 to 4 identified only through maternal serology at delivery.
Patient 1 Patient 2 † Patient 3 † Patient 4 †
Sex  female male male male
Birth weight (g) 1,290 2,460 3,055 3,150
Gestational age 32 weeks 36 weeks 40 weeks 39 weeks
Maternal data** Prenatal care initiated at 
28 weeks, with detection 
of hydrocephalus on fetal 
ultrasound. After positive 
IgG and IgM antibodies to 
toxoplasmosis, treatment 
was initiated, but not 
regularly followed.
Prenatal care including more 
than 10 visits. Negative 
serology in the first trimester. 
At delivery, IgG=930 IU/mL 
IgM=6.87
Prenatal care including  
8 visits. No serum tests for  
T. gondii were requested 
during pregnancy. 
At delivery, IgG=80 IU/mL
IgM=7.28
Only IgG antibodies to  
T. gondii  were investigated 
during prenatal care. 
Positive results in the second 
trimester. In the subsequent 
visit, after 1 month, an IgM 
test was requested, but the 
patient gave birth before she 
could do the test. At delivery, 
IgG=2,640 IU/mL IgM=4.90
Serum tests of the infant at 
birth**
IgG=202 IU/mL  IgM=0.87 IgG=1,720 IU/mL   
IgM=8.03
IgG=40 IU/mL  IgM=7.69 IgG=2,720 IU/mL  
IgM=4.61
Physical examination at  
birth 
Microcephaly
Microphthalmia 
Hepatomegaly
Splenomegaly
Normal Normal at birth.
Splenomegaly and 
hepatomegaly in the 3rd 
week of life.
Normal
Ophthalmologic examination Microphthalmia (right eye). 
Extensive active 
retinochoroiditis in the  
left eye.
Peripheral retinochoroidal 
scar in the left eye. 
Active paramacular 
retinochoroiditis in the right 
eye.
Active macular 
retinochoroiditis in both 
eyes. 
Necrotic lesion and 
vasculitis in the left eye.
Active macular and 
paramacular retinochoroiditis 
in both eyes. Temporal 
papillitis. Vitreous opacity.
Cranial computed 
tomography
Dilated ventricular system.
Cortical cerebral atrophy.
Calcifications in the cortical 
and  subependymal regions, 
and at the basal ganglia.
Multiple cortical and 
subependymal calcifications.
Mildly dilated cerebral 
ventricles.
Punctiform calcifications in 
the thalamus and on the floor 
of the left lateral ventricle.
Normal ventricular system.
Disseminated  punctiform 
calcifications. 
Normal ventricular system.
Follow-up With ventriculo-peritoneal 
shunt from the second week 
of life.
Severe mental and 
neuromotor retardation 
and nearly total visual 
impairment at the age of  
5 years.
Cerebral atrophy, 
microcephaly.
Swallowing impairment, 
with need for gastrostomy.
No need for ventriculo-
peritoneal shunt.
Retinochoroidal scars, 
strabismus, and mild visual 
impairment at the age of  
5 years. No reactivation of 
retinochoroiditis.
Normal mental and 
neuromotor development.
Persistent intracranial 
calcifications. Normal 
cerebral ventricles.
Mild visual impairment.
Normal mental and 
neuromotor development  
at the age of 1 year (was  
lost to follow-up after the 
first year).
Retinochoroidal scars 
at the age of 5 years. 
Moderate visual impairment. 
No reactivation of 
retinochoroiditis.
Normal mental and 
neuromotor development.
Persistent intracranial 
calcifications. Normal 
cerebral ventricles.32  Scientia Medica, Porto Alegre, v. 19, n. 1, p. 27-34, jan./mar. 2009
Screening for Toxoplasma gondii antibodies ...  Lago EG et al.
DISCUSSION
The prevalence of 67.3% of antibodies to T. 
gondii observed in this study is considered to 
be  high,  as  those  in  countries  such  as  France 
(54.3%),17 Belgium (49%)18 or Cuba (71%),19 and 
in other places in Brazil, where the prevalence 
ranges  between  50  and  80%:  Araraquara/SP 
(58%),20  Fortaleza/CE  (71.5%),21  Cuiabá/MT 
(70.7%),22 Londrina/PR (67%),23 and Erechim/
RS (74.5%).24 Two studies conducted at public 
maternity  wards  in  Porto  Alegre  showed 
similar  prevalence  rates  for  antibodies  to  T. 
gondii: 59.8% (95%CI 57.0%-62.5%)25 and 61.1% 
(95%CI 60.2%-62.0%).26 The high prevalence of 
toxoplasmosis  among  women  of  childbearing 
age positively affects the cost-benefit ratio of a 
prenatal screening program, since fewer women 
are likely to have to repeat serum tests during 
pregnancy. Moreover, in a contamination-prone 
environment, susceptible pregnant women, in a 
smaller but not negligible number, are at higher 
risk for toxoplasmosis, and prenatal screening is a 
way to select them for special education regarding 
primary prevention.18, 27, 28 However, among the 
cases of congenital toxoplasmosis observed in this 
study, only one was diagnosed during pregnancy 
(due to abnormal findings on fetal ultrasound). It 
seems that the prenatal screening program with 
only one or two tests in susceptible patients, as 
had been used in Porto Alegre, is not enough to 
detect seroconversion in all patients, although it 
is important to acknowledge that some patients 
probably  benefited  from  treatment  during 
pregnancy.29 Serum tests at delivery were useful 
as a complement to this strategy. Additionally, 
tests  at  delivery  detected  cases  of  congenital 
toxoplasmosis in which the immune status of 
the  mother  was  unknown.  Thus,  in  regions   
with  a  lower  prevalence  of  toxoplasmosis,  in   
which  prenatal  screening  is  not  a  routine   
procedure,  testing  of  parturient  women 
seems  to  be  a  valid  alternative  for  the  early 
detection  of  congenital  toxoplasmosis,  and 
may be complemented by neonatal screening. 
The advantage of delivery screening is that it   
allows  detecting  some  cases  of  congenital 
toxoplasmosis  in  which  T.  gondii-specific  IgM   
is  already  negative  in  the  newborn  infant.  It   
has been shown that around 25% of newborn 
infants  with  congenital  toxoplasmosis  have 
negative  specific  IgM,  and  these  cases  may 
go  undetected  if  only  neonatal  screening  is 
performed.30, 31
Some  cases  of  congenital  toxoplasmosis 
may have gone unnoticed among mothers with 
positive  IgG  and  negative  IgM  results  during 
pregnancy, if the techniques used for prenatal 
testing were not sensitive enough to detect T. 
gondii-specific  IgM  antibodies,  or  in  patients 
infected  during  pregnancy,  but  with  negative 
IgM results at delivery, if T. gondii-specific IgM 
antibodies were too short-lived. Therefore, the 
prevalence of congenital toxoplasmosis may have 
been underestimated.
The increase in the prevalence of immunity 
to  T.  gondii  with  age  is  consistent  with  most 
studies that included this type of analysis.17, 20-22, 
32-34 In our study, as well as in most published 
studies, the increase is more pronounced after 
the age of 30 years. However, unlike populations 
of industrialized countries, in which adolescents 
show a much smaller prevalence of toxoplasmosis, 
with  a  sharper  increase  as  they  grow  older, 
prevalence among Brazilian adolescents is already 
high.17,18,20,22,32-34  This is probably due to the fact 
that exposure to soil and water (major risk factors 
among  children  and  adolescents)  is  the  main   
route of contamination in the Brazilian population, 
whereas in other populations the higher risk is 
posed by food factors, which are more important 
among adults.32-37 The increase in seropositivity 
for toxoplasmosis with age is usually explained 
by the longer exposure to risk factors, but this 
can also be due to the cohort effect, that is, to the 
higher exposure to risk factors in the past, among 
those aged over 30 years.34 Another explanation 
is that the sharp increase in seropositivity for T. 
gondii in women of childbearing age may result 
from the higher susceptibility of pregnant women 
to Toxoplasma infection.38,39 In a Brazilian cohort 
study, pregnancy enhanced all risk factors for 
seroconversion to toxoplasmosis.40
Among the patients considered as having a 
recent infection, a significant number may have 
acquired toxoplasmosis before pregnancy. The 
duration of positivity of T. gondii-specific IgM 
antibodies in postnatal infection has a quite large 
individual variability, and IgM may be detected 
for few weeks or for several years.41-44 The use 
of  very  sensitive  techniques  for  testing  for  T. 
gondii-specific IgM antibodies during pregnancy 
has  been  argued,  since  the  detection  of  these 
antibodies over a long period can lead to the 
incorrect estimation of the timing of infection, 
especially when the first test during pregnancy 
shows  positive  IgM  results.43-45  On  the  other 
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infections (with low antibody titers and high risk 
of mother-to-child transmission) undetected. The 
IgG avidity assay can help identify infections that 
occurred before pregnancy, especially if carried 
out in the first trimester.20, 44-46
Some  mothers  had  already  tested  positive 
for toxoplasmosis before pregnancy, but were 
submitted  to  tests  during  prenatal  care  and 
at delivery, due to the lack of an information 
system across health services, and lack of data 
in their obstetric chart records. The data from 
previous pregnancies are not usually recorded 
in  the  prenatal  chart.  A  similar  situation  was 
identified  in  Italy,  where  a  study  showed   
that 30% of obstetricians and gynecologists did   
not record and did not ask their patients to keep   
the results of their tests for future pregnancies, 
which  caused  patients  to  be  unnecessarily 
retested.47
We observed that the three cases of congenital 
toxoplasmosis  detected  only  through  routine 
testing  of  mothers  at  delivery  had  clinical 
manifestations in the neonatal period. This is not 
in agreement with the international literature, 
in which there is a preponderance of subclinical 
infections.1, 9 This may be related to the findings 
of some researchers that T. gondii strains found in 
Brazil have a higher potential for morbidity than 
in other countries.48-50
We concluded that maternal serologic screening 
at delivery was useful for the early detection of 
cases of congenital toxoplasmosis that would have 
otherwise gone undetected in the neonatal period, 
and allowed for earlier treatment of newborns 
with severe retinochoroiditis. Routine screening 
for Toxoplasma gondii in parturient women should 
be a complement to prenatal screening. In regions 
with low prevalence of toxoplasmosis, this may 
be  an  alternative  strategy.  However,  in  our 
population, the high prevalence of Toxoplasma 
gondii  antibodies  in  pregnant  women  and  of 
congenital  toxoplasmosis  justifies  a  prenatal 
screening program.
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